company background image
RPRX logo

Royalty Pharma NasdaqGS:RPRX Stock Report

Last Price

US$32.63

Market Cap

US$18.4b

7D

-0.6%

1Y

23.6%

Updated

28 May, 2025

Data

Company Financials +

Royalty Pharma plc

NasdaqGS:RPRX Stock Report

Market Cap: US$18.4b

RPRX Stock Overview

Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. More details

RPRX fundamental analysis
Snowflake Score
Valuation6/6
Future Growth2/6
Past Performance4/6
Financial Health4/6
Dividends2/6

Rewards

Trading at 83% below our estimate of its fair value

Earnings are forecast to grow 5.77% per year

Earnings grew by 36.8% over the past year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 27.3%

Risk Analysis

Has a high level of debt

Dividend of 2.7% is not well covered by free cash flows

Significant insider selling over the past 3 months


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

RPRX logo
Royalty Pharma
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts

Patent Cliffs And Regulatory Challenges Will Limit Future Returns

Key Takeaways Global drug pricing reforms, faster generic approvals, and greater regulatory scrutiny threaten the longevity and value of Royalty Pharma’s royalty streams and earnings stability. Rising interest rates and increased competition for royalty assets are compressing margins, elevating acquisition costs, and reducing the company’s financial flexibility and equity appeal.
View narrative
US$32.19
FV
1.4% overvalued intrinsic discount
11.57%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
about 14 hours ago author updated this narrative
RPRX logo
Royalty Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts

Integration Will Generate Over $100 Million In Savings By 2026

Key Takeaways The integration of Royalty Pharma's external manager will boost net margins through significant cost savings and eliminate management fees, enhancing shareholder value. Royalty Pharma's growing pipeline of new therapies and synthetic royalties could significantly drive future revenue growth and earnings, indicating strong market opportunities.
View narrative
US$39.74
FV
17.9% undervalued intrinsic discount
11.42%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
about 15 hours ago author updated this narrative
RPRX logo
Royalty Pharma
AN
AnalystHighTarget
Consensus Narrative from 8 Analysts

Internalization And Acquisition Will Drive Future Efficiency Gains

Key Takeaways Internalization of management and acquisition strategies are expected to enhance financial performance and operational alignment, leading to improved margins and efficiency. Expansion through synthetic royalties and strategic share repurchases demonstrates focus on new revenue streams and maximizing shareholder value.
View narrative
US$47.00
FV
30.6% undervalued intrinsic discount
16.01%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
15 days ago author updated this narrative
View Royalty Pharma Community

Royalty Pharma plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Royalty Pharma
Historical stock prices
Current Share PriceUS$32.63
52 Week HighUS$34.32
52 Week LowUS$24.05
Beta0.48
1 Month Change0.28%
3 Month Change-2.22%
1 Year Change23.65%
3 Year Change-19.81%
5 Year Changen/a
Change since IPO-26.67%

Recent News & Updates

Royalty Pharma: Again, Guidance Raised, Buy Confirmed

May 12

Recent updates

Royalty Pharma: Again, Guidance Raised, Buy Confirmed

May 12

Royalty Pharma: Delivering Growth With A Positive Story Ahead

Feb 13

Subdued Growth No Barrier To Royalty Pharma plc (NASDAQ:RPRX) With Shares Advancing 25%

Jan 29
Subdued Growth No Barrier To Royalty Pharma plc (NASDAQ:RPRX) With Shares Advancing 25%

Royalty Pharma: Key Strategic Updates To Be Priced In

Jan 15

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.22

Jan 13
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.22

We Think Royalty Pharma (NASDAQ:RPRX) Can Stay On Top Of Its Debt

Dec 05
We Think Royalty Pharma (NASDAQ:RPRX) Can Stay On Top Of Its Debt

Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)

Nov 13
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma: Massive Opportunity Ahead

Nov 09

Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21

Oct 14
Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21

Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)

Oct 09
Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Aug 28
Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Aug 22

Royalty Pharma: Busy Putting Capital To Work

Aug 11

Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

Jul 22
Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Shareholder Returns

RPRXUS PharmaceuticalsUS Market
7D-0.6%-0.2%0.8%
1Y23.6%-10.5%11.5%

Return vs Industry: RPRX exceeded the US Pharmaceuticals industry which returned -9.7% over the past year.

Return vs Market: RPRX exceeded the US Market which returned 11.3% over the past year.

Price Volatility

Is RPRX's price volatile compared to industry and market?
RPRX volatility
RPRX Average Weekly Movement3.7%
Pharmaceuticals Industry Average Movement11.4%
Market Average Movement8.0%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market4.2%

Stable Share Price: RPRX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: RPRX's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996n/aPablo Legorretawww.royaltypharma.com

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc Fundamentals Summary

How do Royalty Pharma's earnings and revenue compare to its market cap?
RPRX fundamental statistics
Market capUS$18.38b
Earnings (TTM)US$1.09b
Revenue (TTM)US$2.26b
12.6x
P/E Ratio
6.1x
P/S Ratio

Is RPRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RPRX income statement (TTM)
RevenueUS$2.26b
Cost of RevenueUS$21.72m
Gross ProfitUS$2.24b
Other ExpensesUS$1.15b
EarningsUS$1.09b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)2.59
Gross Margin99.04%
Net Profit Margin48.26%
Debt/Equity Ratio77.8%

How did RPRX perform over the long term?

See historical performance and comparison

Dividends

2.7%
Current Dividend Yield
35%
Payout Ratio

Does RPRX pay a reliable dividends?

See RPRX dividend history and benchmarks
When do you need to buy RPRX by to receive an upcoming dividend?
Royalty Pharma dividend dates
Ex Dividend DateMay 16 2025
Dividend Pay DateJun 10 2025
Days until Ex dividend14 days
Days until Dividend pay date11 days

Does RPRX pay a reliable dividends?

See RPRX dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 11:57
End of Day Share Price 2025/05/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Royalty Pharma plc is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Jason Matthew GerberryBofA Global Research
Geoffrey MeachamCitigroup Inc